文献速递临床试验与 GCP流行病学与生物统计

在巴西家庭或工作场所接触者中预防结核病的利福喷丁联合异烟肼方案:一个月与三个月方案的可接受性与安全性——Ultra-Curto随机对照试验

Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial.
PubMed 文献 · PLoS Med · 2026-02-10

该4期随机试验在巴西两个中心纳入500例无HIV感染、近期有结核暴露且潜伏性结核感染检测阳性的青少年和成人,比较每日1HP与每周3HP方案。1HP组治疗完成率89.6%,3HP组84.1%,差异未达统计学显著;1HP组目标安全性事件或停药发生率16.1%,3HP组10.4%,差异未达统计学显著。两种方案均无优越性。

要点

  • 1HP组治疗完成率89.6%,3HP组84.1%,组间差异未达统计学显著。
  • 1HP组目标>2级安全性事件或停药发生率16.1%,3HP组10.4%,差异未达统计学显著。
  • 两种方案治疗成功率均较高,均无优越性,结果将用于全球结核病预防治疗指南。

核心结论

  • 1HP和3HP均有较高的治疗成功率,分配至1HP的参与者目标安全性事件更多,但多为低级别,两种方案均无优越性。

研究设计与样本

  • 4期随机试验,在巴西两个中心纳入500例无HIV感染、近期有结核暴露且潜伏性结核感染检测阳性的青少年和成人,随机分为1HP组249例和3HP组251例。

主要发现

  • 1HP组治疗完成率89.6%,3HP组84.1%(中心校正风险差5.2%,95%CI [-0.1%, 11.2%],p=0.10)。
  • 1HP组目标>2级安全性事件或停药发生率16.1%,3HP组10.4%(中心校正风险差6.1%,95%CI [-0.04%, 12.3%],p=0.05)。
  • 因任何副作用停药的比例1HP组为7.2%,3HP组为4.4%。
  • 校正中心和基线人口学及临床协变量后,主要安全性结局的风险差为3.4%(95%CI [-2.3%, 9.1%],p=0.24)。
  • 该试验未设计用于确定疗效。

关键数值与推荐

  • 主要结局为经自我报告、药片计数和药理学监测确认的服药完成率>90%及安全性。
  • 治疗安全性定义为发生>2级目标事件或因副作用停药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该试验未设计用于确定疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Short-course tuberculosis preventive therapy with isoniazid and rifapentine (HP) is widely recommended, but the acceptability and safety of one month of daily HP (1HP) compared to three months of weekly HP (3HP) is uncertain. We compared treatment with these two regimens in people with a positive latent tuberculosis infection test and without HIV infection. We hypothesized that 1HP would have greater treatment completion and fewer targeted safety events than 3HP. METHODS AND FINDINGS: We conducted a Phase 4 randomized trial of 1HP versus 3HP in adolescents and adults without HIV infection with recent tuberculosis exposure and a positive latent tuberculosis infection test in two sites in Brazil. The primary outcomes were successful completion of >90% of medication as ascertained by self-report, pill counts, and pharmacologic monitoring, and safety. Treatment safety was defined as occurrence of Grade >2 targeted events or discontinuation of treatment for side effects. We randomized 500 individuals to 1HP (249) and 3HP (251); 193 males and 307 females, with a median age of 39 years. Treatment completion was 89.6% for 1HP recipients versus 84.1% for 3HP recipients (site-adjusted risk difference 5.2%, [95% CI: [-0.1%, 11.2%], p = 0.10). Targeted >Grade 2 adverse safety events or treatment discontinuation occurred in 16.1% of 1HP recipients and 10.4% of 3HP recipients (site-adjusted risk difference 6.1%, [95%CI: [-0.04%, 12.3%], p = 0.05). The proportions who discontinued treatment for any side effect were 7.2% for 1HP and 4.4% for 3HP. The risk difference for the primary safety outcome adjusted for site and baseline demographic and clinical covariates was 3.4% (95% CI [-2.3,9.1%], p = 0.24). The trial was not designed to ascertain efficacy. CONCLUSION: Both 1HP and 3HP had high rates of treatment success. Participants assigned to 1HP had more targeted safety events, mostly low-grade. Neither regimen was superior to the other. These results will inform global guidelines for tuberculosis preventive therapy. NCT04703075 (clinicaltrials.gov).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Durovni B, Cordeiro-Santos M, Cavalcante SC, et al. Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. PLoS Med. 2026. PMID: 41666121. doi:10.1371/journal.pmed.1004758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。